medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2015, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (1)

New international standards for cell therapy and cord blood cell transplantation

Rivero-Jiménez RA

Language: Spanish
References: 20
Page: 65-70
PDF size: 63.64 Kb.


ABSTRACT

Cord Blood Cell (CBC) transplantation is successfully applied for the treatment of various diseases due to the great potential of its advantageous characteristics regarding plasticity and compatibility. Nevertheless, in order to achieve greater levels of applicability, CBC ex vivo expansion cultures are required in certain occasions. As cellular expanded products for transplantation, pre-clinical safety is a great matter of concern before its use. Transplantation and Cellular Therapy Programs should fulfill quality requirements, both national and international, and a certain number of organizations have been dedicated to establish accreditation processes based on standards. Since the draft of the 6th Edition of the International Standards, jointly proposed by The Foundation for the Accreditation of Cellular Therapy and the Joint Accreditation Committee of the International Society for Cellular Therapy and the European Society for the Blood and Bone Transplant (FACT-JACIE), as well as the draft for review and comment of The Common Standards for Cellular Therapies were published, both quality management documents are commented, due to the fact that they establish minimal working guidelines for Programs, Facilities, and Persons working on Cellular Therapies and Transplantation or giving support services for such procedures. Some evidences of the usefulness of this accreditation processes and their importance for achieving better working results in transplantation and cellular therapy are shown.


REFERENCES

  1. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol. 2000;28:1197-1205.

  2. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperim EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335:157-66.

  3. Flores-Guzmán P, Fernández-Sánchez V, Mayani H. Concise Review: Ex Vivo Expansion of Cord Blood-Derived Hematopoietic Stem and Progenitor Cells: Basic Principles, Experimental Approaches, and Impact in Regenerative Medicine. Stem Cells Trans Med 2013;2(11):830-838.

  4. Goldman M, Sher G, Blajchman M Bacterial contamination of cellular blood products: the Canadian perspective. Transfus Sci 2000;23:17-19.

  5. Wang J. Pre-Clinical Transplantation Safety of Hematopoietic Stem/Progenitor Cell Product Expanded from Human Umbilical Cord Blood. J Transplant Technol Res. 2013;3:e120.

  6. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, et al. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42:1356-1364.

  7. WHO. Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser. 1998;878:i-vi,1-101.

  8. FDA. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. U. S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research February 28, 1997. [citado 3 de mayo de 2014] Disponible en: http://www.fda.gov/downloads/biologicsbloodvaccines/safetyavailability/ucm16286 3.pdf

  9. FDA. DOCKET NO. 84N-01541. Draft of Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (1993). [citado 3 de mayo de 2014] Disponible en: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulat oryInformation/OtherRecommendationsforManufacturers/UCM153182.pdf

  10. FACT- JACIE. International Standards for Cellular Therapy Product Collection, Processing, and Administration for Hematopoietic Cellular Therapies. Draft Sixth Edition April 2014. [citado 3 de mayo de 2014] Disponible en: http://www.factwebsite.org/uploadedFiles/Standards/Standards.04.30.14.pdf

  11. Manual de Acreditación y Evaluación. Obtención, Procesamiento y Administración de Productos para la terapia Celular. [citado 14 de junio de 2014] Disponible en: http://www.ont.es/infesp/TejidosPHCelulas/CCA/Auditores/11_ManualDeAcreditacion.pdf

  12. FACT. Common Standards for Cellular Therapies. May 2014. [citado 3 de mayo de 2014] Disponible en: http://www.factwebsite.org/commonstandardsmay2014

  13. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47(6):749-56.

  14. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617-24.

  15. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29(15):1980-6.

  16. ISO 9000 - Quality management. [citado 16 de junio de 2014] Disponible en: http://www.iso.org/iso/home/standards/management-standards/iso_9000.htm

  17. Caunday O, Agulles O, McGrath E, Empereur F, Stoltz JF, Chabannon C. Implementation of JACIE accreditation results in the establishment of new indicators that unevenly monitor processes contributing to the delivery of hematopoietic SCT. Bone Marrow Transplant. 2013;38(4):604-9.

  18. Join Acreditation Committee isct ebmt (JACIE). 2014. [citado 14 de junio de 2014] Disponible en: http://www.jacie.org/

  19. FACT Accredited Organization Search. [citado 14 de junio de 2014] Disponible en: http://www.factwebsite.org/AccreditedSearch.aspx?&type=CellularTherapy&country=A ll&state=All

  20. Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P, et al. Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica. 2014;99(5):908-15.




2020     |     www.medigraphic.com